However, unlike previous studies, this study found that CSGALNACT2 expression is downregulated in ovarian cancer and ovarian cancer metastasis, and high expression is associated with better prognosis in ovarian cancer patients. Here, CSGALNACT2 is linked to ovarian carcinoma.